NCT05017025
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 11 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗
Minor Trial completed Show 4 more changesShow less
- Primary completion date changed from estimate of Jun 7, 2028 to Sep 15, 2026
- Eligibility criteria expanded, about 44 words
- Secondary endpoints: details revised at 1 of 3 entries
- Study description revised
- Notable Primary and study completion pushed from Jun 30, 2026 to Jun 7, 2028v20
- Notable Primary and study completion dates: Jun 30, 2025 to Jun 30, 2026v16
- Study Identification, Study Status, Oversight, Conditionsv13
- Study Identification, Study Status, Oversight, Conditionsv12
Show 5 earlier versionsHide 5 earlier versions
- Notable Primary and study completion dates: May 25, 2024 to Jun 30, 2025v9
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 30 to confirmed 32
- Site details revised
- Minor Eligibility criteria shortened, about 35 wordsv5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 31, 2022 to Feb 17, 2022
- Site details revised
- Study Status, Referencesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Dose-limiting toxicity and recommended phase 2 dose
Timeframe: Up to 30 days after last dose
Secondary (3)
Progression-free survival
Best objective response rate
Overall survival
Arms and interventions
Treatment (osimertinib, aurora A kinase inhibitor LY3295668)Experimental
Patients receive osimertinib PO QD and aurora A kinase inhibitor LY3295668 PO BID on days 1-28. Treatment repeats every 28 days for 24 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
Drugs: Aurora A Kinase Inhibitor LY3295668, Osimertinib
Sites
1 site in 1 country
- M D Anderson Cancer CenterHouston, Texas, United States